Vonoprazan Indications
Vonoprazan is FDA-approved for five specific indications in adults: healing of all grades of erosive esophagitis, maintenance of healed erosive esophagitis, relief of heartburn in non-erosive GERD, and treatment of H. pylori infection (both as triple therapy with amoxicillin/clarithromycin and dual therapy with amoxicillin alone). 1
FDA-Approved Indications
Based on the official drug label, vonoprazan (VOQUEZNA) is indicated for:
1. Erosive Esophagitis
- Healing: 20 mg once daily for 8 weeks for all grades of erosive esophagitis and relief of associated heartburn 1
- Maintenance: 10 mg once daily for up to 6 months to maintain healing and relief of heartburn 1
2. Non-Erosive GERD
- Heartburn relief: 10 mg once daily for 4 weeks 1
3. H. pylori Infection
- Triple therapy: In combination with amoxicillin and clarithromycin 1
- Dual therapy: In combination with amoxicillin alone 1
Clinical Context and Positioning
When to Use Vonoprazan
The 2024 AGA guidelines recommend vonoprazan should be used preferentially for H. pylori eradication in most patients, but generally NOT as first-line therapy for most acid-related conditions due to cost, limited availability, and less long-term safety data. 2
Appropriate Use:
H. pylori eradication (strongest indication): Vonoprazan demonstrates superior eradication rates compared to PPIs (92% vs 80%), with particularly marked benefits in clarithromycin-resistant infections (66-70% vs 32%) 2
Severe erosive esophagitis (LA grade C/D): May be used as a therapeutic option, though superiority over double-dose PPIs remains unproven 2
PPI-refractory GERD: Consider in patients with documented acid-related reflux (LA grade B or greater EE, Barrett's esophagus, peptic stricture, or abnormal pH monitoring) who fail twice-daily PPI therapy 2
Generally NOT Recommended as First-Line:
Mild-moderate erosive esophagitis (LA grade A/B): Similar efficacy to PPIs with healing rates of 92-99% vs 96-100% 2
Non-erosive reflux disease: Limited evidence of superiority; one trial showed only a trend toward benefit (72% vs 62% heartburn-free days, p=0.06) 2
Uninvestigated heartburn: Cost and availability issues outweigh potential benefits when clinical superiority is not established 2
Peptic ulcer disease: No clear advantage over PPIs for treatment or prophylaxis 2
Important Clinical Considerations
Contraindications
- Known hypersensitivity to vonoprazan
- Concurrent use with rilpivirine-containing products 1
Key Warnings
The drug carries standard acid-suppression warnings including risks of gastric malignancy masking, acute tubulointerstitial nephritis, C. difficile infection, bone fractures, vitamin B12 deficiency, hypomagnesemia, and fundic gland polyps 1
Safety Profile
Vonoprazan raises serum gastrin levels higher than PPIs, with elevations persisting throughout treatment but returning toward baseline within weeks of discontinuation. Five-year safety data show comparable adverse event rates to lansoprazole, though long-term data remain more limited than for PPIs 2
Cost-Effectiveness Caveat
Even modest clinical superiority over double-dose PPIs may not justify vonoprazan as first-line therapy given markedly higher costs in the United States. 2 PPIs remain available over-the-counter, while vonoprazan typically requires prior authorization and costs substantially more.